Citadel Advisors’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $97.1M | Buy |
163,800
+113,800
| +228% | +$56.7M | 0.02% | 827 |
|
|
2025
Q4 | $24.4M | Sell |
50,000
-10,300
| -17% | -$4.8M | ﹤0.01% | 2139 |
|
|
2025
Q3 | $25.3M | Buy |
60,300
+50,500
| +515% | +$17M | ﹤0.01% | 2036 |
|
|
2025
Q2 | $2.82M | Sell |
9,800
-500
| -5% | -$149K | ﹤0.01% | 5080 |
|
|
2025
Q1 | $3.18M | Sell |
10,300
-3,200
| -24% | -$1.1M | ﹤0.01% | 4663 |
|
|
2024
Q4 | $4.76M | Sell |
13,500
-800
| -6% | -$294K | ﹤0.01% | 4043 |
|
|
2024
Q3 | $5.12M | Sell |
14,300
-18,800
| -57% | -$6.35M | ﹤0.01% | 3896 |
|
|
2024
Q2 | $10.5M | Buy |
33,100
+2,200
| +7% | +$582K | ﹤0.01% | 2705 |
|
|
2024
Q1 | $7.1M | Buy |
30,900
+19,200
| +164% | +$4.33M | ﹤0.01% | 3420 |
|
|
2023
Q4 | $2.57M | Sell |
11,700
-26,500
| -69% | -$6.11M | ﹤0.01% | 4926 |
|
|
2023
Q3 | $8.63M | Buy |
38,200
+32,600
| +582% | +$7.51M | ﹤0.01% | 2875 |
|
|
2023
Q2 | $1.24M | Sell |
5,600
-1,500
| -21% | -$332K | ﹤0.01% | 6024 |
|
|
2023
Q1 | $1.59M | Sell |
7,100
-19,400
| -73% | -$4.78M | ﹤0.01% | 5802 |
|
|
2022
Q4 | $7.37M | Sell |
26,500
-8,600
| -25% | -$2.17M | ﹤0.01% | 3252 |
|
|
2022
Q3 | $7.35M | Buy |
35,100
+20,200
| +136% | +$4.52M | ﹤0.01% | 3234 |
|
|
2022
Q2 | $3.51M | Sell |
14,900
-14,700
| -50% | -$2.99M | ﹤0.01% | 4469 |
|
|
2022
Q1 | $5.31M | Buy |
29,600
+12,700
| +75% | +$2.42M | ﹤0.01% | 4055 |
|
|
2021
Q4 | $3.65M | Sell |
16,900
-18,300
| -52% | -$3.59M | ﹤0.01% | 4939 |
|
|
2021
Q3 | $6.5M | Sell |
35,200
-3,600
| -9% | -$709K | ﹤0.01% | 3820 |
|
|
2021
Q2 | $6.96M | Sell |
38,800
-67,100
| -63% | -$12.8M | ﹤0.01% | 3745 |
|
|
2021
Q1 | $17.7M | Buy |
105,900
+69,900
| +194% | +$11.7M | ﹤0.01% | 2124 |
|
|
2020
Q4 | $5.46M | Buy |
36,000
+7,800
| +28% | +$1.02M | ﹤0.01% | 3535 |
|
|
2020
Q3 | $2.85M | Buy |
28,200
+5,500
| +24% | +$603K | ﹤0.01% | 4070 |
|
|
2020
Q2 | $2.75M | Buy |
22,700
+2,200
| +11% | +$248K | ﹤0.01% | 4013 |
|
|
2020
Q1 | $1.94M | Sell |
20,500
-71,300
| -78% | -$6.78M | ﹤0.01% | 4185 |
|
|
2019
Q4 | $8.09M | Buy |
91,800
+32,200
| +54% | +$2.83M | ﹤0.01% | 2457 |
|
|
2019
Q3 | $4.75M | Sell |
59,600
-11,400
| -16% | -$918K | ﹤0.01% | 3175 |
|
|
2019
Q2 | $5.54M | Buy |
71,000
+22,500
| +46% | +$2.1M | ﹤0.01% | 2950 |
|
|
2019
Q1 | $5.69M | Buy |
48,500
+33,900
| +232% | +$3.95M | ﹤0.01% | 2818 |
|
|
2018
Q4 | $1.59M | Sell |
14,600
-10,700
| -42% | -$1.24M | ﹤0.01% | 4528 |
|
|
2018
Q3 | $3.23M | Sell |
25,300
-4,000
| -14% | -$495K | ﹤0.01% | 3607 |
|
|
2018
Q2 | $3.31M | Buy |
29,300
+700
| +2% | +$76.9K | ﹤0.01% | 3335 |
|
|
2018
Q1 | $3.21M | Sell |
28,600
-3,000
| -9% | -$381K | ﹤0.01% | 3048 |
|
|
2017
Q4 | $4.67M | Buy |
31,600
+7,800
| +33% | +$992K | ﹤0.01% | 2551 |
|
|
2017
Q3 | $2.79M | Sell |
23,800
-13,700
| -37% | -$1.75M | ﹤0.01% | 3012 |
|
|
2017
Q2 | $4.87M | Buy |
37,500
+11,300
| +43% | +$1.41M | ﹤0.01% | 2163 |
|
|
2017
Q1 | $3.55M | Buy |
26,200
+7,600
| +41% | +$1.15M | ﹤0.01% | 2406 |
|
|
2016
Q4 | $2.67M | Sell |
18,600
-2,900
| -13% | -$370K | ﹤0.01% | 2623 |
|
|
2016
Q3 | $2.54M | Sell |
21,500
-11,400
| -35% | -$1.37M | ﹤0.01% | 2688 |
|
|
2016
Q2 | $3.48M | Buy |
32,900
+2,600
| +9% | +$290K | ﹤0.01% | 2155 |
|
|
2016
Q1 | $3.38M | Buy |
30,300
+4,800
| +19% | +$607K | ﹤0.01% | 2144 |
|
|
2015
Q4 | $3.99M | Sell |
25,500
-6,700
| -21% | -$975K | ﹤0.01% | 2022 |
|
|
2015
Q3 | $4.23M | Sell |
32,200
-4,600
| -13% | -$738K | ﹤0.01% | 2110 |
|
|
2015
Q2 | $6.4M | Sell |
36,800
-3,600
| -9% | -$648K | 0.01% | 1836 |
|
|
2015
Q1 | $6.97M | Buy |
40,400
+16,000
| +66% | +$2.44M | 0.01% | 1712 |
|
|
2014
Q4 | $3.16M | Sell |
24,400
-2,129,300
| -99% | -$274M | ﹤0.01% | 2425 |
|
|
2014
Q3 | $277M | Buy |
2,153,700
+2,121,500
| +6,589% | +$219M | 0.29% | 37 |
|
|
2014
Q2 | $2.85M | Buy |
32,200
+10,700
| +50% | +$1.03M | ﹤0.01% | 2383 |
|
|
2014
Q1 | $2.02M | Sell |
21,500
-13,400
| -38% | -$1.37M | ﹤0.01% | 2649 |
|
|
2013
Q4 | $3.95M | Buy |
34,900
+19,200
| +122% | +$1.73M | 0.01% | 1876 |
|
|
2013
Q3 | $1.24M | Sell |
15,700
-5,700
| -27% | -$417K | ﹤0.01% | 2878 |
|
|
2013
Q2 | $1.41M | Buy |
+21,400
| New | +$1.38M | ﹤0.01% | 2831 |
|
Other funds holding UTHR
ACA
VPM
VCM
Citadel Advisors's UTHR Position: Q1 2026 in Review
Citadel Advisors increased its United Therapeutics (UTHR) stake by 93% in Q1 2026, buying an estimated $86.4M and bringing the position to 360,643 shares worth $214M. The position accounts for 0.03% of the portfolio, ranked #433.
Citadel Advisors first reported a position in UTHR in Q2 2013 and has held it in 50 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.
- Citadel Advisors held 360,643 shares of United Therapeutics worth $214M as of Q1 2026.
- Citadel Advisors bought 173,479 United Therapeutics shares in Q1 2026, an estimated $86.4M.
- United Therapeutics made up 0.03% of Citadel Advisors's portfolio in Q1 2026, its #433 holding.
- Citadel Advisors first reported a position in United Therapeutics in Q2 2013 and has held it in 50 quarters since.
- 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.